Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Cross-Sectional, Observational, Epidemiologic Study to Describe the Burden and the Related factors of Caregivers of Advanced Parkinson's Disease Patients Either Treated with Continuous Dopaminergic Delivery Systems (CSAI or LCIG) or Standard of Care Therapy (SOC)

Trial Profile

A Cross-Sectional, Observational, Epidemiologic Study to Describe the Burden and the Related factors of Caregivers of Advanced Parkinson's Disease Patients Either Treated with Continuous Dopaminergic Delivery Systems (CSAI or LCIG) or Standard of Care Therapy (SOC)

Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Oct 2018

At a glance

  • Drugs Levodopa/carbidopa (Primary) ; Apomorphine
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Acronyms PREDICT
  • Sponsors AbbVie
  • Most Recent Events

    • 09 Oct 2018 New trial record
    • 01 May 2018 Primary endpoint (Caregiver burden and its related factors among caregivers of APD patients using the Zarit Caregiver Burden Interview (ZBI) score:levodopa/carbidopa intestinal gel (LCIG) infusion versus continuous subcutaneous apomorphine infusion (CSAI) and continuation of standard of care (SOC)) has not been met, according to results published in the Journal of Neurology.
    • 01 May 2018 According to results published in the Journal of Neurology, patients were enrolled from Sept 2014 to Sept 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top